DOCSLIB.ORG

203505Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 203505Orig1s000 PHARMACOLOGY REVIEW(S) Comments on N203505 ospemifene From A. Jacobs, AD Date: January 15, 2013 1. I concur that there are no outstanding pharm/tox issues 2. I concur with the proposed pregnancy labeling. 3. I have conveyed some editorial suggestions to the reviewer and they will be addressed as appropriate. Reference ID: 3245227 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- ABIGAIL C JACOBS 01/15/2013 Reference ID: 3245227 DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH PHARMACOLOGY/TOXICOLOGY NDA/BLA REVIEW AND EVALUATION Application number: 203505 Supporting document/s: eCTD Applicant’s letter date: April 25, 2012 CDER stamp date: April 25, 2012 Product: Ospemifene Indication: Vulvar and Vaginal Atrophy in Postmenopausal Women Applicant: Shionogi, Inc. Review Division: Division of Reproductive and Urologic Products Reviewer: Jeffrey Bray, Ph.D. Expert Reviewer/Team Leader: Alex Jordan, Ph.D. Division Director: Hylton Joffe, M.D. Project Manager: George Lyght Disclaimer Except as specifically identified, all data and information discussed below and necessary for approval of NDA 203505 are owned by Shionogi, Inc., or are data for which Shionogi, Inc., has obtained a written right of reference. Any information or data necessary for approval of NDA 203505 that Shionogi, Inc., does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as reflected in the drug’s approved labeling. Any data or information described or referenced below from reviews or publicly available summaries of a previously approved application is for descriptive purposes only and is not relied upon for approval of NDA 203505. 1 Reference ID: 3245246 NDA # 203505 Reviewer: Jeffrey Bray, PhD TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ......................................................................................... 8 1.1 INTRODUCTION .................................................................................................... 8 1.2 BRIEF DISCUSSION OF NONCLINICAL FINDINGS ...................................................... 8 1.3 RECOMMENDATIONS .......................................................................................... 10 2 DRUG INFORMATION .......................................................................................... 12 2.1 DRUG ............................................................................................................... 12 2.2 RELEVANT IND/S, NDA/S, AND DMF/S ............................................................... 13 2.3 DRUG FORMULATION ......................................................................................... 13 2.5 COMMENTS ON IMPURITIES/DEGRADANTS OF CONCERN ....................................... 13 2.6 PROPOSED CLINICAL POPULATION AND DOSING REGIMEN .................................... 16 3 STUDIES SUBMITTED.......................................................................................... 17 3.1 STUDIES REVIEWED........................................................................................... 17 3.2 STUDIES NOT REVIEWED ................................................................................... 18 3.3 PREVIOUS REVIEWS REFERENCED...................................................................... 19 4 PHARMACOLOGY................................................................................................ 19 4.1 PRIMARY PHARMACOLOGY ................................................................................. 19 4.3 SAFETY PHARMACOLOGY................................................................................... 19 5 PHARMACOKINETICS/ADME/TOXICOKINETICS .............................................. 24 5.1 PK/ADME........................................................................................................ 24 5.2 TOXICOKINETICS ............................................................................................... 37 6 GENERAL TOXICOLOGY..................................................................................... 38 6.1 SINGLE-DOSE TOXICITY ..................................................................................... 38 6.2 REPEAT-DOSE TOXICITY .................................................................................... 39 7 GENETIC TOXICOLOGY ...................................................................................... 65 7.1 IN VITRO REVERSE MUTATION ASSAY IN BACTERIAL CELLS (AMES)....................... 65 7.2 IN VITRO ASSAYS IN MAMMALIAN CELLS.............................................................. 67 7.3 IN VIVO CLASTOGENICITY ASSAY IN RODENT (MICRONUCLEUS ASSAY).................. 69 7.4 OTHER GENETIC TOXICITY STUDIES.................................................................... 70 8 CARCINOGENICITY ............................................................................................. 71 9 REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY .............................. 109 9.1 FERTILITY AND EARLY EMBRYONIC DEVELOPMENT............................................. 109 9.2 EMBRYONIC FETAL DEVELOPMENT ................................................................... 109 9.3 PRENATAL AND POSTNATAL DEVELOPMENT ....................................................... 114 10 SPECIAL TOXICOLOGY STUDIES................................................................. 125 11 INTEGRATED SUMMARY AND SAFETY EVALUATION............................... 128 2 Reference ID: 3245246 NDA # 203505 Reviewer: Jeffrey Bray, PhD 12 APPENDIX/ATTACHMENTS........................................................................... 139 3 Reference ID: 3245246 NDA # 203505 Reviewer: Jeffrey Bray, PhD Table of Tables Table 1 List of Impurities .............................................................................................. 14 Table 2 Potential Impurities in Ospemifene (FC-1271a) Drug Substance.................... 15 Table 3 Batches Used for Toxicological and Clinical Studies; Analysis Results and the Uses of Batches ............................................................................................................ 16 Table 4 Summary of Supportive Stability Results in HDPE Bottles and Blisters .......... 16 Table 5 Inhibition of Ospemifene Oxidations to M4 and M5 Metabolites in Human Liver Microsomes using CYP Enzyme Selective Inhibitors .................................................... 26 Table 6 Formation of 4’-hydroxy ospemifene with CYP Specific Inhibitors.................. 27 Table 7 Comparison of M1 and M2 Metabolite Exposure to the Parent Ospemifene... 29 Table 8 CYP-associated Activities in vitro in Liver Microsomes from Female Rats...... 30 Table 9 CYP-associated Activities in vitro in Liver Microsomes from Female Cynomolgus Monkeys................................................................................................... 30 Table 10 Inhibition of CYP Enzymes by Ospemifene................................................... 31 Table 11 Inhibition of CYP Enzymes by 4-hydroxy ospemifene ................................... 32 Table 12 Inhibitory potency of 4’-hydroxy ospemifene (HM-136) towards CYP activities in the incubations with a pool of human liver microsomes............................................. 33 Table 13 Animals Replaced During First 4 Weeks of Treatment.................................. 73 Table 14 Male Mice Sacrificed Early during 2-Year Oral Ospemifene Carcinogenicity Study Due to Urogenital Swelling.................................................................................. 74 Table 15 Disposition of Female Mice during a 2-Year Oral Ospemifene Carcinogenicity Study............................................................................................................................. 75 Table 16 Mean Body Weight Gain (g) for Female Mice during a 2-Year Oral Ospemifene Carcinogenicity Study ............................................................................... 77 Table 17 Type and Incidence of Protruding Organs in Male Mice Sacrificed Before Week 13 and After Dosing Cessation Week 14 ............................................................ 78 Table 18 Selected Macroscopic Findings of Note in Female Mice at Necropsy during a 2-Year Oral Ospemifene Carcinogenicity Study (n=51 total/group)............................... 78 Table 19 Selected Neoplastic Findings of Note in Female Mice at Necropsy during a 2- Year Oral Ospemifene Carcinogenicity Study (n=51/group) ......................................... 80 Table 20 Adrenal and Ovary Neoplastic Findings in Female Mice at Necropsy during a 2-Year Oral Ospemifene Carcinogenicity Study............................................................ 81 Table 21 List of Statistically Significant Increasing Dose-Response Neoplasms with P- Values and % Incidence (Combined Fatal+Non-fatal) from a 2-Year Oral Ospemifene Carcinogenicity Study.................................................................................................... 82 Table
Recommended publications
  • Eraas for Menopause Treatment: Welcome the ‘Designer Estrogens’

    Eraas for Menopause Treatment: Welcome the ‘Designer Estrogens’

    REVIEW CME LEARNING OBJECTIVE: Readers will tailor hormone therapy to the needs of the patient CREDIT HEATHER D. HIRSCH, MD, MS, NCMP ELIM SHIH, MD, NCMP HOLLY L. THACKER, MD, NCMP Assistant Professor, Clinical Internal Medicine, Division Department of Obstetrics and Gynecology, Director of Center for Specialized Women’s Health, of General Internal Medicine, The Ohio State University, Women’s Health Institute, Cleveland Clinic Department of Obstetrics and Gynecology, Women’s Columbus, and Center for Women’s Health, Health Institute, Cleveland Clinic; Professor, Cleveland The Ohio State University Wexner Medical Center, Clinic Lerner College of Medicine of Case Western Upper Arlington, OH Reserve University, Cleveland, OH ERAAs for menopause treatment: Welcome the ‘designer estrogens’ ABSTRACT strogen receptor agonist-antagonists E(ERAAs), previously called selective es- Estrogen receptor agonist-antagonists (ERAAs) selec- trogen receptor modulators (SERMs), have tively inhibit or stimulate estrogen-like action in targeted extended the options for treating the vari- tissues. This review summarizes how ERAAs can be used ous conditions that menopausal women suffer in combination with an estrogen or alone to treat meno- from. These drugs act differently on estrogen pausal symptoms (vasomotor symptoms, genitourinary receptors in different tissues, stimulating re- syndrome of menopause), breast cancer or the risk of ceptors in some tissues but inhibiting them breast cancer, osteopenia, osteoporosis, and other female in others. This allows selective inhibition or midlife concerns. stimulation of estrogen-like action in various target tissues.1 KEY POINTS This article highlights the use of ERAAs Tamoxifen is approved to prevent and treat breast cancer. to treat menopausal vasomotor symptoms It may also have beneficial effects on bone and on car- (eg, hot flashes, night sweats), genitourinary diovascular risk factors, but these are not approved uses.
  • The Mechanisms and Managements of Hormone-Therapy Resistance in Breast and Prostate Cancers

    The Mechanisms and Managements of Hormone-Therapy Resistance in Breast and Prostate Cancers

    Endocrine-Related Cancer (2005) 12 511–532 REVIEW The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers K-M Rau1,2*, H-Y Kang3,4*, T-L Cha1,5,6, S A Miller1 and M-C Hung1 1Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA 2Department of Hematology-Oncology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, Taiwan 3Graduate Institute of Clinical Medical Sciences, Chang Gung University, Kaohsiung, Taiwan 4The Center for Menopause and Reproductive Medicine Research, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, Taiwan 5Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA 6Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (Requests for offprints should be addressed to M-C Hung; Email: [email protected]) *(K-M Rau and H-Y Kang contributed equally to this work) Abstract Breast and prostate cancer are the most well-characterized cancers of the type that have their development and growth controlled by the endocrine system. These cancers are the leading causes of cancer death in women and men, respectively, in the United States. Being hormone-dependent tumors, antihormone therapies usually are effective in prevention and treatment. However, the emergence of resistance is common, especially for locally advanced tumors and metastatic tumors, in which case resistance is predictable. The phenotypes of these resistant tumors include receptor- positive, ligand-dependent; receptor-positive, ligand-independent; and receptor-negative, ligand- independent. The underlying mechanisms of these phenotypes are complicated, involving not only sex hormones and sex hormone receptors, but also several growth factors and growth factor re- ceptors, with different signaling pathways existing alone or together, and with each pathway possibly linking to one another.
  • Clinical Update on the Use of Ospemifene in the Treatment of Severe Symptomatic Vulvar and Vaginal Atrophy

    Clinical Update on the Use of Ospemifene in the Treatment of Severe Symptomatic Vulvar and Vaginal Atrophy

    Journal name: International Journal of Women’s Health Article Designation: Review Year: 2016 Volume: 8 International Journal of Women’s Health Dovepress Running head verso: Palacios and Cancelo Running head recto: The use of ospemifene in the treatment of severe symptomatic VVA open access to scientific and medical research DOI: http://dx.doi.org/10.2147/IJWH.S110035 Open Access Full Text Article REVIEW Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy Santiago Palacios1 Abstract: The physiological decrease in vaginal estrogens is accountable for the emergence of María Jesús Cancelo2 vulvar and vaginal atrophy (VVA) and its related symptoms such as vaginal dryness, dyspareunia, vaginal and/or vulvar irritation or itching, and dysuria. The repercussion of these symptoms 1Palacios Institute of Women’s Health, Madrid, Spain; 2Gynecology and on quality of life often makes it necessary to initiate treatment. Up until now, the treatments Obstetrics Department, Guadalajara available included vaginal moisturizers and lubricants, local estrogens, and hormonal therapy. University Hospital, University of Alcalá, Spain However, therapeutic options have now been increased with the approval of 60 mg ospemifene, the first nonhormonal oral treatment with an agonist effect on the vaginal epithelium and an endometrial and breast safety profile which makes it unique. This is the first selective estrogen receptor modulator indicated in women with moderate-to-severe vaginal atrophy not eligible For personal use only. for local estrogen treatment. Considering that “local estrogen noneligible women” are those in whom such treatment cannot be administered either because it is contraindicated or due to skill issues, who are averse to the mode and convenience of vaginal products’ administration or to their use on account of potential systemic absorption, or those who demonstrate dissatisfac- tion in terms of efficacy and safety, it is clear that there is a significant unmet medical need in VVA management.
  • Management of Women with Premature Ovarian Insufficiency

    Management of Women with Premature Ovarian Insufficiency

    Management of women with premature ovarian insufficiency Guideline of the European Society of Human Reproduction and Embryology POI Guideline Development Group December 2015 1 Disclaimer The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the current clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the European field of human reproduction and embryology. This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients. However, adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override the healthcare professional's clinical judgment in diagnosis and treatment of particular patients. Ultimately, healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical judgment, knowledge, and expertise, and taking into account the condition, circumstances, and wishes of the individual patient, in consultation with that patient and/or the guardian or carer. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.
  • In Vitro and in Silico Analyses of the Inhibition of Human Aldehyde Oxidase By

    In Vitro and in Silico Analyses of the Inhibition of Human Aldehyde Oxidase By

    JPET Fast Forward. Published on July 9, 2019 as DOI: 10.1124/jpet.119.259267 This article has not been copyedited and formatted. The final version may differ from this version. JPET #259267 In Vitro and In Silico Analyses of the Inhibition of Human Aldehyde Oxidase by Bazedoxifene, Lasofoxifene, and Structural Analogues Shiyan Chen, Karl Austin-Muttitt, Linghua Harris Zhang, Jonathan G.L. Mullins, and Aik Jiang Lau Downloaded from Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore jpet.aspetjournals.org (S.C., A.J.L.); Institute of Life Science, Swansea University Medical School, United Kingdom (K.A-M, J.G.L.M.); NanoBioTec, LLC., Whippany, New Jersey, U.S.A. (L.H.Z.); at ASPET Journals on September 29, 2021 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (A.J.L.) 1 JPET Fast Forward. Published on July 9, 2019 as DOI: 10.1124/jpet.119.259267 This article has not been copyedited and formatted. The final version may differ from this version. JPET #259267 Running Title In Vitro and In Silico Analyses of AOX Inhibition by SERMs Corresponding author: Dr. Aik Jiang Lau Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543. Downloaded from Tel.: 65-6601 3470, Fax: 65-6779 1554; E-mail: [email protected] jpet.aspetjournals.org Number of text pages: 35 Number of tables: 4 Number of figures: 8 at ASPET Journals on September 29, 2021 Number of references 60 Number of words in Abstract (maximum
  • 1 Disposition of Lasofoxifene, a Next Generation Selective Estrogen Receptor Modulator, in Healthy Male Subjects Chandra Prakash

    1 Disposition of Lasofoxifene, a Next Generation Selective Estrogen Receptor Modulator, in Healthy Male Subjects Chandra Prakash

    DMD Fast Forward. Published on March 27, 2008 as DOI: 10.1124/dmd.108.020404 DMD FastThis article Forward. has not beenPublished copyedited on and March formatted. 27, The 2008 final version as doi:10.1124/dmd.108.020404 may differ from this version. “DMD #20404” DISPOSITION OF LASOFOXIFENE, A NEXT GENERATION SELECTIVE ESTROGEN RECEPTOR MODULATOR, IN HEALTHY MALE SUBJECTS CHANDRA PRAKASH, KIM A JOHNSON AND MARK J GARDNER, Pfizer Global Research and Development, Groton, CT, USA Downloaded from dmd.aspetjournals.org at ASPET Journals on September 24, 2021 1 Copyright 2008 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on March 27, 2008 as DOI: 10.1124/dmd.108.020404 This article has not been copyedited and formatted. The final version may differ from this version. “DMD #20404” Running title: In vivo and in vitro metabolism of lasofoxifene Address for Correspondence: Chandra Prakash, Ph. D. Pharmacokinetics, Dynamics and Metabolism Pfizer Global Research and Development Downloaded from Groton, CT 06340 Ph. No. 860-441-6415 Fax No. 860-686-0654 dmd.aspetjournals.org email: [email protected] Text pages 33 at ASPET Journals on September 24, 2021 Tables 4 Figures 9 References 31 Abstract 245 Introduction 484 Discussion 1487 1 Abbreviations used are: SERM, selective estrogen receptor modulator; EPT, estrogen- progestin replacement therapy; ER, estrogen receptor; SRM, single reaction monitoring; SAM, S-adenosyl methionine; ABT, aminobenzotriazole; ICH, international conference on harmonization; GCP, Good Clinical Practices; MTBE, methyl-tert-butyl ether; COMT, catechol-O-methyltransferase; UGT, UDP-glucuronosyltransferase; UDPGA, UDP- glucuronic acid. 2 DMD Fast Forward.
  • Medication Use for the Risk Reduction of Primary Breast Cancer in Women: a Systematic Review for the U.S

    Medication Use for the Risk Reduction of Primary Breast Cancer in Women: a Systematic Review for the U.S

    Evidence Synthesis Number 180 Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA-290-2015-00009-I, Task Order No. 7 Prepared by: Pacific Northwest Evidence-Based Practice Center Oregon Health & Science University Mail Code: BICC 3181 SW Sam Jackson Park Road Portland, OR 97239 www.ohsu.edu/epc Investigators: Heidi D. Nelson, MD, MPH Rongwei Fu, PhD Bernadette Zakher, MBBS Marian McDonagh, PharmD Miranda Pappas, MA L.B. Miller, BA Lucy Stillman, BS AHRQ Publication No. 19-05249-EF-1 January 2019 This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (HHSA-290-2015-00009-I, Task Order No. 7). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
  • WO 2009/137104 Al

    WO 2009/137104 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 12 November 2009 (12.11.2009) WO 2009/137104 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/137 (2006.01) A61K 31/5685 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/138 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/4196 (2006.01) CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, PCT/US2009/002885 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, 7 May 2009 (07.05.2009) NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, (25) Filing Language: English UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/127,025 9 May 2008 (09.05.2008) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): RA¬ TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, DIUS HEALTH, INC.
  • Lasofoxifene Cuts Fractures After Menopause

    Lasofoxifene Cuts Fractures After Menopause

    26 ENDOCRINOLOGY APRIL 15, 2010 • INTERNAL MEDICINE NEWS Lasofoxifene Cuts Fractures After Menopause ‘A significant effect … was not evident until 5 years, fractures also is similar to that observed treat 492 patients for 1 year to prevent a in women taking other antiresorptive single major coronary event,” she said. and absolute risk reductions were very small.’ therapies, and it stands in contrast to The PEARL investigators said that la- raloxifene’s inability to reduce this risk, sofoxifene raised the risk of venous BY MARY ANN MOON benefits over raloxifene for the skeleton, they said. thromboembolism to a similar degree as breast, heart, or reproductive tract. However, Dr. Becker noted in her ed- do raloxifene, tamoxifen, and oral estro- he investigational drug lasofox- “Given the plethora of drugs current- itorial that nearly all the reduction in gen therapies. Like these agents, laso- ifene decreases the risk of verte- ly available for osteoporosis, studies of risk for nonvertebral fractures could be foxifene also significantly increased the Tbral and nonvertebral fractures new agents should show clear benefits attributed to forearm and wrist frac- rate of hot flushes and leg cramps. It did in postmenopausal women with osteo- over existing agents,” she wrote. Results tures. “A significant effect in the overall not raise the risk of endometrial cancer porosis, according to a report. of the PEARL study do not do so, Dr. group was not evident until 5 years, and or endometrial hyperplasia. The nonsteroidal selective estrogen- Becker added. absolute risk reductions were very Dr. Becker countered that although receptor modulator (SERM) also reduces Dr.
  • Prevention and Treatment of Osteoporosis with Selective Estrogen-Receptor Modulators (SERMS)

    Prevention and Treatment of Osteoporosis with Selective Estrogen-Receptor Modulators (SERMS)

    Prevention and Treatment of Osteoporosis with Selective Estrogen-Receptor Modulators (SERMS) - a revival? Rozenberg S, Eyckerman M Homepage: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen www.kup.at/ 2011; 18 (Sonderheft 2), 4-5 mineralstoffwechsel Online-Datenbank mit Autoren- und Stichwortsuche Member of the Offizielles Organ der Österreichische Gesellschaft Österreichische Indexed in SCOPUS/EMBASE/Excerpta Medica Österreichischen Gesellschaft für Orthopädie und Gesellschaft zur Erforschung des Knochens Orthopädische Chirurgie für Rheumatologie www.kup.at/mineralstoffwechsel und Mineralstoffwechsels P.b.b. GZ02Z031108M, Verlagspostamt: 3002 Purkersdorf, Erscheinungsort: 3003 Gablitz P.b.b. GZ02Z031108M, Verlagspostamt: 3002 Purkersdorf, Erscheinungsort: 3003 Gablitz Prevention and Treatment of Osteoporosis with Selective Estrogen-Receptor Modulators (SERMS) – a revival? S. Rozenberg, M. Eyckerman This review analyses the efficacy of selective estrogen-receptor 0.89) [5]. In the STAR-study (Tam versus RAL in 19,647 post- modulators (SERMs) in postmenopausal osteoporosis treatment menopausal women with increased 5-year breast cancer risk), based on meta-analyses or randomized controlled trials (RCTs). RAL was shown to be as effective as tamoxifen in reducing the We also refer to a consensus paper [1]. risk of invasive breast cancer but not non-invasive breast can- cer, but RAL was associated with a higher safety (lower risk of thromboembolic events and cataracts) [7]. A more recent meta- ! Tibolone analysis by Kanis et al [8] evaluated the distribution of fracture risk assessed at baseline using the FRAX tool in RCT with RAL Tibolone is viewed by some as a menopause hormone therapy in the MORE-trial and determined the efficacy of RAL as a rather than as a SERM.
  • CP.PMN.168 Ospemifene (Osphena)

    CP.PMN.168 Ospemifene (Osphena)

    Clinical Policy: Ospemifene (Osphena) Reference Number: CP.PMN.168 Effective Date: 08.28.18 Last Review Date: 11.20 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Ospemifene (Osphena®) is a selective estrogen receptor modulator (SERM). FDA Approved Indication(s) Osphena is indicated for the treatment of moderate to severe dyspareunia and vaginal dryness, symptoms of vulvar and vaginal atrophy, due to menopause. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Osphena is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Dyspareunia or Vaginal Dryness (must meet all): 1. Diagnosis of dyspareunia or vaginal dryness due to menopause; 2. Age ≥ 18 years; 3. Failure of two vaginal lubricants or vaginal moisturizers at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced; 4. Failure of ≥ 4 weeks of one vaginal estrogen at up to maximally indicated doses (e.g., estradiol vaginal cream, Premarin vaginal cream), unless contraindicated or clinically significant adverse effects are experienced; 5. Dose does not exceed 60 mg (1 tablet) per day. Approval duration: Medicaid/HIM – 12 months Commercial – Length of Benefit B. Other diagnoses/indications 1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub

    US 20090226431A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub. Date: Sep. 10, 2009 (54) TREATMENT OF CANCER AND OTHER Publication Classification DISEASES (51) Int. Cl. A 6LX 3/575 (2006.01) (76)76) InventorInventor: Nabilabil Habib,Habib. Beirut (LB(LB) C07J 9/00 (2006.01) Correspondence Address: A 6LX 39/395 (2006.01) 101 FEDERAL STREET A6IP 29/00 (2006.01) A6IP35/00 (2006.01) (21) Appl. No.: 12/085,892 A6IP37/00 (2006.01) 1-1. (52) U.S. Cl. ...................... 424/133.1:552/551; 514/182: (22) PCT Filed: Nov.30, 2006 514/171 (86). PCT No.: PCT/US2O06/045665 (57) ABSTRACT .."St. Mar. 6, 2009 The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3B.5C,6C.-triol), its production, its use, and to methods of treating neoplasms and other tumors as Related U.S. Application Data well as other diseases including hypercholesterolemia, (60) Provisional application No. 60/741,725, filed on Dec. autoimmune diseases, viral diseases (e.g., hepatitis B, hepa 2, 2005. titis C, or HIV), and diabetes. F2: . - 2 . : F2z "..., . Cz: ".. .. 2. , tie - . 2 2. , "Sphagoshgelin , , re Cls Phosphatidiglethanolamine * - 2 .- . t - r y ... CBs .. A . - . Patent Application Publication Sep. 10, 2009 Sheet 1 of 16 US 2009/0226431 A1 E. e'' . Phosphatidylcholine. " . Ez'.. C.2 . Phosphatidylserias. * . - A. z' C. w E. a...2 .". is 2 - - " - B 2. Sphingoshgelin . Cls Phosphatidglethanglamine Figure 1 Patent Application Publication Sep. 10, 2009 Sheet 2 of 16 US 2009/0226431 A1 Chile Phosphater Glycerol Phosphatidylcholine E.